|
TMEM219 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.07199804588731E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.95550037168846E-10 |
| Normal-vs-Stage2 |
1.360450E-04 |
| Normal-vs-Stage3 |
2.42269999617406E-08 |
| Normal-vs-Stage4 |
8.17420000021052E-07 |
| Stage1-vs-Stage2 |
4.979400E-01 |
| Stage1-vs-Stage3 |
3.638800E-01 |
| Stage1-vs-Stage4 |
8.285000E-01 |
| Stage2-vs-Stage3 |
9.402600E-01 |
| Stage2-vs-Stage4 |
6.436800E-01 |
| Stage3-vs-Stage4 |
5.967400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.59300383784489E-11 |
| Normal-vs-AfricanAmerican |
1.163370E-03 |
| Normal-vs-Asian |
2.14159999956109E-07 |
| Caucasian-vs-AfricanAmerican |
9.828200E-01 |
| Caucasian-vs-Asian |
6.250400E-01 |
| AfricanAmerican-vs-Asian |
7.033800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.21589993418559E-10 |
| Normal-vs-Female |
1.05520037152473E-10 |
| Male-vs-Female |
2.944200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.11489999454761E-08 |
| Normal-vs-Age(41-60Yrs) |
8.0670026214591E-11 |
| Normal-vs-Age(61-80Yrs) |
2.76239999985606E-07 |
| Normal-vs-Age(81-100Yrs) |
7.117700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.649400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.931600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.350200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.342800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.798800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.602400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.250200E-01 |
| Classical-VS-Follicular |
2.087000E-01 |
| Classical-VS-Other |
8.231600E-01 |
| Classical-VS-Normal |
2.18840001675602E-09 |
| Tall-VS-Follicular |
2.932600E-01 |
| Tall-VS-Other |
9.771600E-01 |
| Tall-VS-Normal |
1.320490E-02 |
| Follicular-VS-Other |
5.713400E-01 |
| Follicular-VS-Normal |
1.46969999947899E-07 |
| Other-VS-Normal |
1.984180E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.26454443874991E-12 |
| Normal-vs-N1 |
4.47100000000589E-05 |
| N0-vs-N1 |
6.445400E-01 |
|
|
